Analysis of a molecular genetic neuro-oncology study with partially biased selection.

Rebecca Betensky, David N. Louis, J. Gregory Cairncross

Research output: Contribution to journalArticle

Abstract

Oligodendrogliomas are a common variant of malignant brain tumors, and are unique for their relative sensitivity to chemotherapy and better prognosis. For these reasons, the identification of an objective oligodendroglial marker has been a long sought-after goal in the field of neuro-oncology. To this end, 75 patients who received chemotherapy at the London Regional Cancer Centre between 1984 and 1999 were studied (Ino et al., Clinical Cancer Research, 7, 839-845, 2001). Of these 75 patients, 50 were initially treated with chemotherapy (the current practice) and comprise a population-based sample. The remaining 25 patients were initially treated with radiation and were included in the study only because their tumor recurred, at which time they received chemotherapy. Because this group of 25 patients included neither those radiation patients whose tumors never recurred nor those radiation patients whose tumors recurred but were not treated with chemotherapy, issues of selection bias were of concern. For this reason, the initial analysis of these data included only the 50 population-based patients. This was unsatisfying given the rarity of this disease and of genetic information on this disease and led us to question whether we could undertake an analysis that includes all of the patients. Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients.

Original languageEnglish (US)
Pages (from-to)167-178
Number of pages12
JournalBiostatistics (Oxford, England)
Volume4
Issue number2
DOIs
StatePublished - Jan 1 2003

Fingerprint

Oncology
Chemotherapy
Biased
Tumor
Radiation
Cancer
Brain Tumor
Selection Bias
Prognosis
Entire
Costs

ASJC Scopus subject areas

  • Statistics and Probability
  • Statistics, Probability and Uncertainty

Cite this

Analysis of a molecular genetic neuro-oncology study with partially biased selection. / Betensky, Rebecca; Louis, David N.; Cairncross, J. Gregory.

In: Biostatistics (Oxford, England), Vol. 4, No. 2, 01.01.2003, p. 167-178.

Research output: Contribution to journalArticle

@article{6dfcbd6bd844444c86d88353ffad3920,
title = "Analysis of a molecular genetic neuro-oncology study with partially biased selection.",
abstract = "Oligodendrogliomas are a common variant of malignant brain tumors, and are unique for their relative sensitivity to chemotherapy and better prognosis. For these reasons, the identification of an objective oligodendroglial marker has been a long sought-after goal in the field of neuro-oncology. To this end, 75 patients who received chemotherapy at the London Regional Cancer Centre between 1984 and 1999 were studied (Ino et al., Clinical Cancer Research, 7, 839-845, 2001). Of these 75 patients, 50 were initially treated with chemotherapy (the current practice) and comprise a population-based sample. The remaining 25 patients were initially treated with radiation and were included in the study only because their tumor recurred, at which time they received chemotherapy. Because this group of 25 patients included neither those radiation patients whose tumors never recurred nor those radiation patients whose tumors recurred but were not treated with chemotherapy, issues of selection bias were of concern. For this reason, the initial analysis of these data included only the 50 population-based patients. This was unsatisfying given the rarity of this disease and of genetic information on this disease and led us to question whether we could undertake an analysis that includes all of the patients. Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients.",
author = "Rebecca Betensky and Louis, {David N.} and Cairncross, {J. Gregory}",
year = "2003",
month = "1",
day = "1",
doi = "10.1093/biostatistics/4.2.167",
language = "English (US)",
volume = "4",
pages = "167--178",
journal = "Biostatistics",
issn = "1465-4644",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Analysis of a molecular genetic neuro-oncology study with partially biased selection.

AU - Betensky, Rebecca

AU - Louis, David N.

AU - Cairncross, J. Gregory

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Oligodendrogliomas are a common variant of malignant brain tumors, and are unique for their relative sensitivity to chemotherapy and better prognosis. For these reasons, the identification of an objective oligodendroglial marker has been a long sought-after goal in the field of neuro-oncology. To this end, 75 patients who received chemotherapy at the London Regional Cancer Centre between 1984 and 1999 were studied (Ino et al., Clinical Cancer Research, 7, 839-845, 2001). Of these 75 patients, 50 were initially treated with chemotherapy (the current practice) and comprise a population-based sample. The remaining 25 patients were initially treated with radiation and were included in the study only because their tumor recurred, at which time they received chemotherapy. Because this group of 25 patients included neither those radiation patients whose tumors never recurred nor those radiation patients whose tumors recurred but were not treated with chemotherapy, issues of selection bias were of concern. For this reason, the initial analysis of these data included only the 50 population-based patients. This was unsatisfying given the rarity of this disease and of genetic information on this disease and led us to question whether we could undertake an analysis that includes all of the patients. Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients.

AB - Oligodendrogliomas are a common variant of malignant brain tumors, and are unique for their relative sensitivity to chemotherapy and better prognosis. For these reasons, the identification of an objective oligodendroglial marker has been a long sought-after goal in the field of neuro-oncology. To this end, 75 patients who received chemotherapy at the London Regional Cancer Centre between 1984 and 1999 were studied (Ino et al., Clinical Cancer Research, 7, 839-845, 2001). Of these 75 patients, 50 were initially treated with chemotherapy (the current practice) and comprise a population-based sample. The remaining 25 patients were initially treated with radiation and were included in the study only because their tumor recurred, at which time they received chemotherapy. Because this group of 25 patients included neither those radiation patients whose tumors never recurred nor those radiation patients whose tumors recurred but were not treated with chemotherapy, issues of selection bias were of concern. For this reason, the initial analysis of these data included only the 50 population-based patients. This was unsatisfying given the rarity of this disease and of genetic information on this disease and led us to question whether we could undertake an analysis that includes all of the patients. Here we examine approaches for utilizing the entire study population, as well as the assumptions required for doing so. We illustrate that there are both costs and benefits to using the 25 selected patients.

UR - http://www.scopus.com/inward/record.url?scp=0142058741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142058741&partnerID=8YFLogxK

U2 - 10.1093/biostatistics/4.2.167

DO - 10.1093/biostatistics/4.2.167

M3 - Article

C2 - 12925514

AN - SCOPUS:0142058741

VL - 4

SP - 167

EP - 178

JO - Biostatistics

JF - Biostatistics

SN - 1465-4644

IS - 2

ER -